MINNEAPOLIS--(BUSINESS WIRE)--Consistent with its commitment to addressing unmet patient needs, Medtronic, Inc. (NYSE: MDT), today announced the first enrollment in the company’s FDA-approved clinical trial of its self-expanding (SE) Complete SE stent for the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA).
